CA2244256A1 - Antipruritic - Google Patents

Antipruritic

Info

Publication number
CA2244256A1
CA2244256A1 CA002244256A CA2244256A CA2244256A1 CA 2244256 A1 CA2244256 A1 CA 2244256A1 CA 002244256 A CA002244256 A CA 002244256A CA 2244256 A CA2244256 A CA 2244256A CA 2244256 A1 CA2244256 A1 CA 2244256A1
Authority
CA
Canada
Prior art keywords
antipruritic
new
derivative
new morphinan
opiate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002244256A
Other languages
French (fr)
Other versions
CA2244256C (en
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Junzo Kamei
Kuniaki Kawamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries, Inc.
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Junzo Kamei
Kuniaki Kawamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2244256(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries, Inc., Hiroshi Nagase, Jun Utsumi, Takashi Endoh, Toshiaki Tanaka, Junzo Kamei, Kuniaki Kawamura filed Critical Toray Industries, Inc.
Publication of CA2244256A1 publication Critical patent/CA2244256A1/en
Application granted granted Critical
Publication of CA2244256C publication Critical patent/CA2244256C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Abstract

This invention provides an antipruritic comprising an opiate .kappa. receptor agonist as an effective component, a new morphinan quaternary ammonium salt derivative and a new morphinan-N-oxide derivative which are useful in treating pruritus complicated with some diseases.
CA002244256A 1996-11-25 1997-11-21 Antipruritic Expired - Lifetime CA2244256C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP313476/96 1996-11-25
JP31347696 1996-11-25
PCT/JP1997/004267 WO1998023290A1 (en) 1996-11-25 1997-11-21 Antipruritic agent

Publications (2)

Publication Number Publication Date
CA2244256A1 true CA2244256A1 (en) 1998-06-04
CA2244256C CA2244256C (en) 2006-07-11

Family

ID=18041771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002244256A Expired - Lifetime CA2244256C (en) 1996-11-25 1997-11-21 Antipruritic

Country Status (15)

Country Link
US (2) US6174891B1 (en)
EP (5) EP1310255B1 (en)
KR (1) KR100557801B1 (en)
CN (3) CN1291717C (en)
AT (3) ATE263563T1 (en)
AU (1) AU738743B2 (en)
CA (1) CA2244256C (en)
DE (3) DE69737592T2 (en)
DK (1) DK0897726T3 (en)
ES (3) ES2215158T3 (en)
NO (1) NO316309B1 (en)
NZ (1) NZ331001A (en)
PT (1) PT897726E (en)
TW (1) TW542838B (en)
WO (1) WO1998023290A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
DE69637416T2 (en) * 1996-12-24 2009-01-22 George F. Long Beach Elkhoury TOPICAL APPLICATION OF OPIOIDES, SUCH AS MORPHINE, TO REDUCE JUCKREIZ AND SKIN DISEASES, AND SKIN IRRITATION
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
JP3211027B2 (en) * 1998-11-13 2001-09-25 丸石製薬株式会社 Topical containing capsaicin
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
DE60039444D1 (en) * 1999-08-24 2008-08-21 Toray Industries REMEDIES FOR NEUROPATHIC PAIN AND EXPERIMENTAL MODELS OF NEUROPATHIC PAIN
WO2001074819A1 (en) * 2000-04-03 2001-10-11 Toray Industries, Inc. Analgesics containing morphinan n-oxide derivatives as the active ingredient
JP2002249442A (en) * 2001-02-21 2002-09-06 Fumakilla Ltd Medicine for hyposensitization therapy of allergy
DE60231388D1 (en) * 2001-03-30 2009-04-16 Toray Industries MEANS TO TREAT THE SYNDROME OF UNRANDY LEGS
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
JP4239592B2 (en) * 2001-05-08 2009-03-18 東レ株式会社 Sepsis treatment
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
KR101035931B1 (en) 2002-03-29 2011-05-23 산텐 세이야꾸 가부시키가이샤 ?-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
JP5189242B2 (en) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド Abuse-resistant pharmaceutical composition
JP4806190B2 (en) * 2002-09-25 2011-11-02 ユーロ−セルティーク エス．エイ． N-substituted hydromorphones and their use
TW200533355A (en) 2004-03-30 2005-10-16 Toray Industries Antipruritic agent
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
CN101137658B (en) * 2005-03-10 2011-06-08 东丽株式会社 Antipruritic agent for pruritus caused by multiple sclerosis
CN101155814B (en) 2005-04-06 2010-06-16 东丽株式会社 Crystals of morphinan derivative and process for producing the same
CA2628971C (en) * 2005-11-09 2014-02-11 Toray Industries, Inc. Therapeutic or prophylactic agent for functional bowel disorder
EP1974731B1 (en) * 2005-12-21 2011-07-13 Toray Industries, Inc. Morphinan derivatives for use as antitussive agents
AU2007297827B2 (en) * 2006-09-20 2012-09-20 Mallinckrodt Llc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
CA2680205C (en) * 2007-03-06 2015-06-30 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
KR101477043B1 (en) 2007-04-24 2014-12-29 도레이 카부시키가이샤 Therapeutic or prophylactic agent for dyskinesia
PL2151241T3 (en) 2007-04-26 2012-08-31 Toray Industries Stable solid preparation comprising 4,5-epoxymorphinan derivative
JP5343848B2 (en) * 2007-06-22 2013-11-13 東レ株式会社 Treatment or prevention of schizophrenia
RU2440117C1 (en) * 2007-10-05 2012-01-20 Торэй Индастриз, Инк. Therapeutic agent for improvement of skin properties containing morphinan derivative or any of its pharmacologically acceptable acid-additive salts as active ingredient
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
EP2896614B1 (en) * 2008-05-27 2017-07-12 Mallinckrodt LLC Processes and compounds for the preparation of normorphinans
EP2331508B1 (en) 2008-09-03 2014-11-12 Mallinckrodt LLC Substituted berbines and processes for their synthesis
WO2010096791A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010096788A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinanium quaternary salts and processes for their production
CN102325777B (en) * 2009-02-23 2015-08-12 马林克罗特公司 (+)-morphinan * N-oxide compound and preparation method thereof
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
KR101732042B1 (en) 2010-01-29 2017-05-02 도레이 카부시키가이샤 Therapeutic or prophylactic agent for biliary diseases
US9006262B2 (en) 2011-01-31 2015-04-14 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
WO2013036729A1 (en) 2011-09-08 2013-03-14 Mallinckrodt Llc Production of alkaloids without the isolation of intermediates
JP6064252B2 (en) * 2012-01-19 2017-01-25 三笠製薬株式会社 Pruritus-improving transdermal patch
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2014093871A1 (en) * 2012-12-14 2014-06-19 Trevi Therapeutics, Inc. Methods for treating pruritus
JPWO2016052617A1 (en) * 2014-09-30 2017-09-21 国立大学法人 筑波大学 Nalfurafine-containing topical preparation
TW201707703A (en) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd Soft capsule preparation
CN106866688B (en) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 It is a kind of receive furan draw coffee refining methd
CN109310656A (en) * 2016-03-21 2019-02-05 特雷维治疗股份有限公司 The treatment of uremic pruritus
TW201821108A (en) * 2016-12-06 2018-06-16 大陸商江蘇恆瑞醫藥股份有限公司 [kappa] opioid receptor agonist in the preparation of a medicament for the treatment of pruritus induced by farnesoid X receptor agonist
US20210015813A1 (en) 2018-03-08 2021-01-21 Victoria Link Ltd. Treatment of demyelinating diseases
CN112703000A (en) 2018-07-23 2021-04-23 特雷维治疗股份有限公司 Treatment of chronic cough, shortness of breath and dyspnea
EP3950059A4 (en) * 2019-03-29 2023-01-11 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
KR20230031207A (en) 2020-06-30 2023-03-07 도레이 카부시키가이샤 Agents for improving or preventing symptoms of muscle weakness in diseases or syndromes accompanying metabolic abnormalities
KR20240035395A (en) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 Urea derivatives that can be used in cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
PT94070A (en) * 1989-05-18 1991-01-08 Glaxo Group Ltd PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES
WO1993015081A1 (en) * 1992-01-23 1993-08-05 Toray Industries, Inc. Morphinan derivative and medicinal use
JPH06122677A (en) * 1992-08-28 1994-05-06 Sankyo Co Ltd Optically active carboxamide derivative
CA2143318A1 (en) * 1993-06-30 1995-01-12 Hiroshi Nagase Antitussive agents
CA2174619A1 (en) * 1993-10-20 1995-04-27 Kenneth Donald Vaughan Ibuprofen and flurbiprofen as anti-pruritic agents
IT1273751B (en) 1994-02-11 1997-07-10 Smithkline Beecham Farma AZACYCLIC DERIVATIVES
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
NO983431D0 (en) 1998-07-24
KR100557801B1 (en) 2006-04-21
DE69728585T2 (en) 2004-08-05
EP1312361A1 (en) 2003-05-21
EP0897726A4 (en) 2003-05-28
CN1214634A (en) 1999-04-21
DE69728585D1 (en) 2004-05-13
CA2244256C (en) 2006-07-11
JP3531170B2 (en) 2004-05-24
EP0897726B1 (en) 2007-04-11
EP1327444B1 (en) 2005-03-23
ATE291429T1 (en) 2005-04-15
PT897726E (en) 2007-07-09
CN1530111A (en) 2004-09-22
EP1310251A1 (en) 2003-05-14
NZ331001A (en) 2000-05-26
TW542838B (en) 2003-07-21
NO983431L (en) 1998-09-24
CN1291717C (en) 2006-12-27
DE69732868T2 (en) 2006-04-13
US6316461B1 (en) 2001-11-13
ES2215158T3 (en) 2004-10-01
CN1180844C (en) 2004-12-22
EP0897726A1 (en) 1999-02-24
DE69737592T2 (en) 2008-01-03
US6174891B1 (en) 2001-01-16
EP1310255B1 (en) 2004-04-07
NO316309B1 (en) 2004-01-12
DE69732868D1 (en) 2005-04-28
DK0897726T3 (en) 2007-08-13
WO1998023290A1 (en) 1998-06-04
ES2285733T3 (en) 2007-11-16
EP1310255A1 (en) 2003-05-14
CN1535687A (en) 2004-10-13
EP1327444A1 (en) 2003-07-16
AU738743B2 (en) 2001-09-27
ATE359076T1 (en) 2007-05-15
KR19990081978A (en) 1999-11-15
ES2236630T3 (en) 2005-07-16
ATE263563T1 (en) 2004-04-15
DE69737592D1 (en) 2007-05-24
AU4968397A (en) 1998-06-22

Similar Documents

Publication Publication Date Title
CA2244256A1 (en) Antipruritic
EP0628911A3 (en) Test program generator.
DE69623398D1 (en) Automotive alternator,
HUP9802337A3 (en) Process for activating polysaccharides, polysaccharides produced by this process, and use thereof
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
HK1058874A1 (en) Method for forming program guides.
AU3841999A (en) Preloaded ic-card and method for authenticating the same
AU1693197A (en) Articles and methods for treating fabrics based on acyloxyalkyl quaternary ammonium compositions
ZA961946B (en) Receptor activation by gas6.
ZA966579B (en) O/W emulsion composition for eye drops.
AU3167095A (en) Pth or pthrp antagonists
AU3742595A (en) Process for producing oligoamines or polyamines
PL346365A1 (en) N-alkyl ammonium acetonitrile salts, methods therefor and compositions therewith
EP1035861A4 (en) Threonine-containing protegrins
HK1026596A1 (en) Method for determining data for treating the cornea
EP0617005A3 (en) Triarylamine compound, process for producing the same and electrophotographic photoreceptor using the same.
ZA978841B (en) Aqueous dispersions.
ZA994105B (en) Method for treating glaucoma.
AU2248195A (en) Opiate receptor ligands
EP0623630A3 (en) Water-in-oil polymer emulsions, process for their preparation and their use.
AU3741797A (en) Quaternary ammonium salt compositions, and methods for treating substrates
WO1996039425A3 (en) Compounds having bradykinin antagonistic activity and mu-opioid agonistic activity
ZA988840B (en) Method for treating sexual dysfunction.
ZA985239B (en) Quaternary ammonium compounds.
HK1033551A1 (en) Method for treating copd.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20171121